Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines.
Peptide trimming in the endoplasmic reticulum (ER), the final step required for the generation of most HLA class I-binding peptides, implicates the concerted action of two aminopeptidases, ERAP1 and ERAP2. Because defects in the expression of these peptidases could lead to aberrant surface HLA class I expression in tumor cells, we quantitatively assayed 14 EBV-B cell lines and 35 human tumor cell lines of various lineages for: 1) expression and enzymatic activities of ERAP1 and ERAP2; 2) ER peptide-trimming activity in microsomes; 3) expression of HLA class I H chains and TAP1; and 4) surface HLA class I expression. ERAP1 and ERAP2 expression was detectable in all of the EBV-B and tumor cell lines, but in the latter it was extremely variable, sometimes barely detectable, and not coordinated. The expression of the two aminopeptidases corresponded well to the respective enzymatic activities in most cell lines. A peptide-trimming assay in microsomes revealed additional enzymatic activities, presumably contributed by other unidentified aminopeptidases sharing substrate specificity with ERAP2. Interestingly, surface HLA class I expression showed significant correlation with ERAP1 activity, but not with the activity of either ERAP2 or other unidentified aminopeptidases. Transfection with ERAP1 or ERAP2 of two tumor cell lines selected for simultaneous low expression of the two aminopeptidases resulted in the expected, moderate increases of class I surface expression. Thus, low and/or imbalanced expression of ERAP1 and probably ERAP2 may cause improper Ag processing and favor tumor escape from the immune surveillance.
Fruci
Doriana
D
Research Center Ospedale Bambino Gesù, Rome, Italy. fruci@med.uniroma2.it
Ferracuti
Silvia
S
Limongi
Maria Zaira
MZ
Cunsolo
Veronica
V
Giorda
Ezio
E
Fraioli
Rocco
R
Sibilio
Leonardo
L
Carroll
Oliver
O
Hattori
Akira
A
van Endert
Peter M
PM
Giacomini
Patrizio
P
D000626:Aminopeptidases / Q000235:genetics* / Q000378:metabolism*; D017951:Antigen Presentation; D001402:B-Lymphocytes / Q000201:enzymology* / Q000276:immunology; D001483:Base Sequence; D002460:Cell Line; D045744:Cell Line, Tumor; D002472:Cell Transformation, Viral; D004247:DNA / Q000235:genetics; D004721:Endoplasmic Reticulum / Q000201:enzymology; D015870:Gene Expression; D004854:Herpesvirus 4, Human; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D008223:Lymphoma / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D008545:Melanoma / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D015778:Minor Histocompatibility Antigens; D014162:Transfection
D015395:Histocompatibility Antigens Class I; D015778:Minor Histocompatibility Antigens; D004247:DNA; D000626:Aminopeptidases; C464841:ERAP1 protein, human; C503944:ERAP2 protein, human